Patents by Inventor Jou-Ku Chung

Jou-Ku Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PLASMA KALLIKREIN ANTIBODY DOSING REGIMENS FOR TREATING HEREDITARY ANGIOEDEMA
    Publication number: 20240343829
    Abstract: The invention describes methods for administering anti-plasma kallikrein antibodies, e.g., dosing regimens, to treat plasma kallikrein associated disorders, including hereditary angioedema (HAE).
    Type: Application
    Filed: March 25, 2024
    Publication date: October 17, 2024
    Inventors: Jou-Ku Chung, Christopher John Morabito, Andrew John Nichols
  • USE OF ANTI-IL-27 ANTIBODIES
    Publication number: 20240026001
    Abstract: The present disclosure relates to methods of treating cancer comprising administering to a subject an anti-IL-27 antibody and pembrolizumab.
    Type: Application
    Filed: May 24, 2023
    Publication date: January 25, 2024
    Inventors: Alison O'NEILL, Lauren HARSHMAN, Jonathan HILL, Jou-Ku CHUNG, Kerry WHITE, Robert ROSS
  • USE OF ANTI-IL-27 ANTIBODIES
    Publication number: 20240025987
    Abstract: The present disclosure relates to methods of treating cancer comprising administering to a subject an anti-IL-27 antibody, atezolizumab, and bevacizumab.
    Type: Application
    Filed: May 24, 2023
    Publication date: January 25, 2024
    Inventors: Alison O'NEILL, Lauren HARSHMAN, Jonathan HILL, Jou-Ku CHUNG, Kerry WHITE, Robert ROSS
  • METHODS OF TREATING CANCER WITH AN ANTI-CD39 ANTIBODY AND PEMBROLIZUMAB
    Publication number: 20230036592
    Abstract: The invention provides methods and uses of treating cancer with and IgG4 anti-CD39_229p antibody in combination with pembrolizumab, wherein the IgG4 anti-CD39_229p antibody is provided at particular doses and dosages.
    Type: Application
    Filed: June 2, 2022
    Publication date: February 2, 2023
    Inventors: Alison O'NEILL, Jou-Ku CHUNG, Robert ROSS, Andrew LAKE
  • ANTI-IL-27 ANTIBODIES AND USES THEREOF
    Publication number: 20220389089
    Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof at a dose of at least about 0.003 mg/kg to at least about 20 mg/kg.
    Type: Application
    Filed: May 6, 2022
    Publication date: December 8, 2022
    Applicant: Surface Oncology, Inc.
    Inventors: Alison O'NEILL, Lauren HARSHMAN, Jonathan HILL, Jou-Ku CHUNG, Kerry WHITE, Robert ROSS, Benjamin LEE
  • Methods of Treating Cancer with an Anti-CD39 Antibody
    Publication number: 20220389115
    Abstract: The invention provides methods of treating cancer using an anti-CD39 antibody or fragment thereof as monotherapy or in combination with other therapies at particular dosages and frequencies.
    Type: Application
    Filed: June 1, 2022
    Publication date: December 8, 2022
    Applicant: Surface Oncology, Inc.
    Inventors: Andrew Lake, Alison M. O'NEILL, Jou-Ku Chung, Robert Ross
  • Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency
    Publication number: 20220072152
    Abstract: The present invention provides, among other things, methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need of treatment a composition comprising an mRNA encoding an ornithine transcarbamylase protein at a low dose and at an administration interval such that at least one symptom or feature of the OTC deficiency is reduced.
    Type: Application
    Filed: September 27, 2021
    Publication date: March 10, 2022
    Inventors: Kim Askew, Jou-Ku Chung, Frank DeRosa, Michael Heartlein, Shrirang Karve, Thomas McCauley, Lianne Smith, Ann J. Barbier
  • Composition and methods for treatment of ornithine transcarbamylase deficiency
    Patent number: 11167043
    Abstract: The present invention provides, among other things, methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need of treatment a composition comprising an mRNA encoding an ornithine transcarbamylase protein at a low dose and at an administration interval such that at least one symptom or feature of the OTC deficiency is reduced.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 9, 2021
    Assignee: TRANSLATE BIO, INC.
    Inventors: Kim Askew, Jou-Ku Chung, Frank DeRosa, Michael Heartlein, Shrirang Karve, Thomas McCauley, Lianne Smith, Ann J. Barbier
  • OCULAR DISTRIBUTION AND PHARMACOKINETICS OF LIFITEGRAST FORMULATIONS
    Publication number: 20200009130
    Abstract: The present invention provides lifitegrast formulations useful for the treatment of immune-related diseases of the ocular surface. The formulations and methods provided herein are particularly useful for treatment of ocular anterior segment tissues.
    Type: Application
    Filed: December 15, 2017
    Publication date: January 9, 2020
    Applicant: SARcode Bioscience Inc.
    Inventors: Jou-Ku CHUNG, Elizabeth SPENCER, Matthew HUNT, Devin WELTY, Thomas MCCAULEY
  • Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency
    Publication number: 20190192688
    Abstract: The present invention provides, among other things, methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need of treatment a composition comprising an mRNA encoding an ornithine transcarbamylase protein at a low dose and at an administration interval such that at least one symptom or feature of the OTC deficiency is reduced.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: Kim Askew, Jou-Ku Chung, Frank DeRosa, Michael Heartlein, Shrirang Karve, Thomas McCauley, Lianne Smith, Ann J. Barbier